

Table 1: Summary of genes examined by real-time PCR analysis.

Gene Symbol	Gene Name	RefSeq Transcript ID	Reference
<i>Kit</i>	kit oncogene	NM_021099	15
<i>Fcrla</i>	Fc fragment of IgE, high affinity I, receptor for α polypeptide	NM_010184	16
<i>Mcpt1</i>	mast cell protease 1	NM_008570	17, 18
<i>Mcpt2</i>	mast cell protease 2	NM_008571	19
<i>Mcpt4</i>	mast cell protease 4	NM_010779	2, 20
<i>Cma2</i>	chymase 2, mast cell (mast cell protease 10)	NM_001024714	14*
<i>Anxa10</i>	annexin A10	NM_011922	21
<i>Ctse</i>	cathepsin E	NM_007799	22
<i>Fos</i>	FBJ osteosarcoma oncogene	NM_010234	23
<i>Ptgr1</i>	Prostaglandin reductase 1 (leukotriene B ₄ 12-hydroxydehydrogenase)	NM_025968	24 (porcine)
<i>Cnn1</i>	calponin 1	NM_009922	25
<i>Ces3</i>	carboxylesterase 3	NM_053200	26
<i>Cpe</i>	carboxypeptidase E	NM_013494	27 (bovine)
<i>Notch4</i>	Notch gene homolog 4	NM_010929	28
28S rRNA	28S ribosomal RNA	NR_003279	29

*, The coding sequence presented in this paper is the N-terminus truncated-form of *Cma2*, while the RefSeq "NM_001024714" is the complete sequence of *Cma2*.


We next investigated whether the Notch4 protein is exclusively present in sMCs by immunostaining of stomach tissue (Figure 6a). Notch4 signals were detected in the nucleus-like structures of sMCs but not in those of mMCs. Furthermore, Notch4 signals were also found in the skin MCs, which were adjacently clustered with sMCs (Figure 3a). These results show that Notch4 is present in sMCs but not in mMCs, and suggest that Notch4 participates in sMC-specific transcription of Notch-target genes, which may be required for some sMC functions. In hematopoietic cells, it has been reported that constitutively active Notch4 promotes the expansion of progenitor cells and inhibits myeloid differentiation [32]. Since Notch ligands have been shown to exist in connective tissues such as skin dermis [33], it will be interesting to explore whether Notch4 plays a role in the differentiation of sMCs and the maintenance of sMC functions.

The *Ptgr1* product, 15-oxo-prostaglandin 13-reductase/leukotriene (LT) B₄ 12-hydroxydehydrogenase is an essential enzyme for inactivation of eicosanoids such as prostaglandin E₂ (PGE₂) and LTB₄ [34]. Although it has been reported that the pathways of eicosanoid synthesis differ among the different MC subclasses [1,4], our results suggest that the inactivation system of eicosanoids also varies among the MC subclasses. *Ptgr1* expression was found to be significantly higher in the separately pooled mMCs by real-time RT-PCR (data not shown). We also examined *Ptgr1* expression in stomach sections by immunostaining. Signals for the *Ptgr1* protein were found in granule-like structures of mMCs in the stomach mucosa but not in sMCs (Figure 6b), suggesting that the *Ptgr1* enzyme may be released from mMCs upon degranulation. Since PGE₂ plays critical roles in the maintenance of gut homeostasis through mucosal protection and inhibition of acid secre-

tion, it is possible that when activated, mMCs negatively regulate the cytoprotective actions of PGE₂ through rapid inactivation by *Ptgr1*.

Gene expression pattern of extracellular matrix components, adhesion molecules, and cytoskeletal proteins in sMCs and mMCs

MC phenotypes have been shown to depend on their interactions with the surrounding extracellular matrices (ECMs) and neighboring cells [1]. One of the most remarkable findings in this study is the difference in gene expression of ECM protein components, adhesion molecules, and cytoskeletal proteins, which may reflect functional adaptation of each type of MC to the mucosal or submucosal environment in the stomach (Figure 5b). mMCs express genes for mucosa-specific ECM proteins such as *Muc1* (Mucin) and *Tff1* (Trefoil factor), while sMCs express genes for conventional ECM proteins such as *Col4a* (procollagen) and *Lama2* (laminin). Moreover, sMCs express genes for adhesion molecules such as *Alcam* and *Vcam1*, and genes for ordinary cytoskeletal proteins such as *Acta2* (actin), while mMCs express desmosome-component genes such as *Dsc2* (desmocollin) and *Dsg2* (desmoglein), and genes for keratin intermediate filaments such as *Krt8* and *Krt19*. Desmosomes were reported to be present in the stomach epithelia [35], and it was found that desmosome-like structures are detected in a particular type of MC [36]. It is thus possible that mMCs interact with adjacent epithelia through desmosomal adhesion in the stomach. In contrast, sMCs appear to interact with neighboring cells via adhesion molecules such as VCAM-1, ALCAM and VE-cadherin (*Vcam1*, *Alcam1* and *Cdh5*). Since these adhesion molecules have been shown to be involved in dynamic regulation of the actin cytoskeleton [37,38], such molecule-mediated inter-



b

Functional Category	sMC-rich (CL1-3)	mMC-rich (CL4-7)
MHC Class I	<i>H2-D1, H2-K, H2-Q7, H2-Q10</i>	
MHC Class II		<i>H2-Aa, H2-Eb1</i>
Protease	<i>Mpt4, Mcpt5, Mcpt6, Cma2, Cpe, Ctsl</i>	<i>Mcpt1, Mcpt2, Ctse</i>
Eicosanoid-related		<i>Ptgr1, Pla2g12</i>
Transcription-Associated Factor	<i>Notch4, Notch1, Barx1, Bcl6, Etv1, Madh1, Sox18</i>	<i>Foxa1, Fos, Sox2</i>
Signal Transduction	<i>Gnai1, Gnal2, Rgs2, Gnao, Sfrp1</i>	
Adhesion Molecule	<i>Alcam, Cdh5, Vcam1</i>	<i>Dsc2, Dsg2</i>
Receptor-related	<i>C1qr1, Eng, Il6st, Nptxr, Pdgfra,</i>	<i>Tnfrsf1b</i>
Cytoskeleton	<i>Acta2, Actg2, Cnn1, Des, Dstn, Myh11, Myl9, Pdlim3, Prph1, Stmn2, Tagln</i>	<i>Krt 8, Krt17, Krt18, Krt19</i>
Secretion		<i>Muc1, Tff1, Tff2</i>
Extracellular Matrix	<i>Bgn, Col4a1, Dcn, Fbln2, Lama2, Lamb2, Lum, Mglap, Pmp22, Sparcl1</i>	
Miscellaneous	<i>Ces3, Hdc</i>	<i>Anxa10</i>

Figure 5

Clustering analysis of the gene expression profiles between sMCs and mMCs. (a) Representation of mRNA expression levels of sMC₁₋₃ and mMC₁₋₃ compared with BMMCs. The color of the bars represents the ratio of signal intensity between independent samples and BMMCs, according to the scale shown on the top right. Genes with significantly different expression between sMCs and mMCs ($p < 0.05$, Limma's t test) were selected (1,272 genes) and classified into 7 clusters using the k -means algorithm (CL1-7). (b) Functional categorization of representative genes from (a).




Figure 6

Immunohistochemical analysis of Notch4 and Ptgr1 in sMCs and mMCs in stomach tissue. (a) Stomach submucosa (sMCs; left panels), stomach mucosa (mMCs; middle panels) and skin (skin MCs; right panels) sections were stained with an anti-Notch4 antibody (lower panels) and with toluidine blue (upper panels). sMCs stained with the anti-Notch4 antibody in the gastric submucosa and skin dermis are indicated by arrows. No staining was observed in mMCs (arrowheads) localized in the gastric mucosa. sMCs and mMCs were metachromatically stained with toluidine blue. (b) Stomach submucosa (sMCs; left panels) and stomach mucosa (mMCs; right panels) sections were stained with an anti-Ptgr1 antibody (lower panels) and with toluidine blue (upper panels). No staining with the anti-Ptgr1 antibody was found in the sMCs (arrow). Small signals were observed in the mMCs (arrowheads). sMCs and mMCs were metachromatically stained with toluidine blue. Bars, 25 μ m (a, b).

actions with submucosal cells may be critical to maintain the functional and morphological properties of sMCs. Indeed, it should be noted that most sMCs are variable in shape, and are often stretched and winding as compared with mMCs [1].

Conclusion

We established a method of RNA amplification from pooled intact MCs isolated from frozen tissue sections, which enables us to conveniently obtain the global gene expression pattern of MCs from various tissues, organs, and species including humans. By using this method, we demonstrated for the first time the distinct gene expression profiles of submucosal and mucosal MCs in the mouse stomach. Our findings offer insight into possible unidentified properties specific for each MC subclass.

Methods

Materials

The following materials were obtained from the sources indicated: HPLC purified T7-(dT)₂₄ primer [5'-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGCCGG(T)₂₄] from GE Healthcare UK Ltd. (Buckinghamshire, England), RNase-free water, dNTP, SuperScript II, *Escherichia coli* (*E. coli*) RNase H, *E. coli* DNA polymerase I, *E. coli* DNA ligase, T4 DNA polymerase and random hexamers from Invitrogen (San Diego, CA), RNase inhib-

itor, glycogen, and MEGAscript T7 kit from Ambion (Austin, TX). Balb/c mice were obtained from JapanClea (Hamamatsu, Japan). This study was approved by the Committee on Animal Research of Kyoto University Graduate School of Pharmaceutical Sciences.

RNA amplification and oligonucleotide microarray

Mouse interleukin-3-dependent BMMCs were prepared as described previously [39]. Total RNA of BMMCs was extracted using RNeasy mini kit (Qiagen, Valencia, CA). Five micrograms of total RNA from BMMCs were labeled and prepared for hybridization according to the manufacturer's instructions (standard protocol). On the other hand, 30 μ g, 10 μ g and 2 μ g of BMMC total RNA were amplified and labeled by our original three-round amplification method, which is described below.

First round

Total RNA was incubated with T7-(dT)₂₄ primer and first-strand cDNA was then synthesized by SuperScript II (Invitrogen). Second-strand synthesis was carried out by adding RNase H, DNA polymerase I and DNA ligase. The antisense RNA was synthesized using MEGAscript T7 kit.

Second round

The antisense RNA product was annealed with random hexamers, and cDNA was again synthesized by Super-

Script II. Then, the RNA-cDNA hybrid was digested with RNase H and annealed with the T7-(dT)₂₄ primer, and then second-strand synthesis was carried out by adding DNA polymerase I. The antisense RNA was again synthesized using MEGAscript T7 kit. Quality and size distribution of the antisense RNA product were confirmed by an RNA 6000 Nano LabChip on the Agilent Bioanalyzer (Palo Alto, CA).

Third round

As in the case of the second round, the double-stranded cDNA with a T7-promoter sequence was prepared from the second-round RNA product. Biotin-labeled antisense RNA was synthesized by RNA Transcript Labeling Kit (Enzo, Farmingdale, NY).

These labeled RNAs were hybridized to GeneChip Murine Expression oligonucleotide arrays (Affymetrix, Santa Clara, CA). We used microarray suite 5.0 of Affymetrix GeneChip Operating Software for quantification of the GeneChip data and decision of "Presence" or "Absence" of expression of each probe set using the values of 11 paired (perfect-matched and mismatched) probes.

Microdissection of MCs from tissue sections, RNA extraction, and microarray data analysis

Tissue sections 7 µm in thickness were prepared using a Jung Frigocut 3000E cryostat (Leica, Nussloch, Germany), and thaw-mounted onto poly-L-lysine-coated glass slides. To visualize MCs, the sections were fixed with Carnoy's fixative, and immersed in toluidine blue using the following protocol: Carnoy's fixative for 1 min, RNase-free water for 10 sec, toluidine blue (0.5% in 0.12N hydrochloric acid) for 5 sec, RNase-free water for 10 sec, 70% ethanol for 15 sec, and 100% ethanol for 15 sec three times; the sections were then vacuumed for 10 min to dry. Each single MC was microdissected from the sections using a patch pipette, and 15 cells were collected with an LCM Cap using the PixCell IIe Laser Capture Microdissection System (Arcturus, Mountain View, CA). As a negative control, LCM Caps just put on tissue sections without MCs were subjected to the same protocols (no cell). Fifteen microdissected MCs were homogenized in denaturing buffer of RNeasy mini kits. Twenty nanograms of poly G (Sigma, Saint Louis, MO) was added to the lysate as a nucleic acid carrier, and total RNA was extracted. Fifty picograms of BMMC total RNA (BMMC-amp) and total RNAs extracted from sMCs in the stomach submucosa, mMCs in the stomach mucosa and skin MCs in the ear dermis were amplified and labeled using the three-round amplification method, and were hybridized to U74Av2 Murine Genome Array (Affymetrix). On the other hand, total RNA of BMMCs (BMMC-std) and peritoneal MC, which were collected from mouse peritoneal cavities and purified by density gradient centrifugation using metrizamide, were

labeled and hybridized by the standard protocol. Raw microarray data of macrophages (E-MEXP-38/298290452) and fibroblasts (E-GEOD-6697/1629511747) using the standard protocol were obtained from ArrayExpress, a public repository for transcriptomics data. We used either microarray suite 5.0 of Affymetrix GeneChip Operating Software or the robust multi-array average (RMA) expression measure for log transformation (\log_2) and normalization of the GeneChip data [40,41]. To determine the similarity in the data, hierarchical clustering analysis and PCA using the R statistical environment <http://www.r-project.org> were performed as a visualization technique. For comparison of the expression profiles of sMCs with that of mMCs, we selected 1,272 genes identified as having significantly different expression levels by the Limma's *t*-test ($p < 0.05$, $n = 3$). Signal values of sMCs and mMCs were normalized by the signal values of BMMCs. Using the *k*-means clustering algorithm, these genes were classified into seven clusters on the basis of similarity of their expression profiles.

Real-time reverse-transcription polymerase chain reaction (RT-PCR)

Total RNA extracted from 60 captured MCs was subjected to real-time RT-PCR. Real-time PCR was performed in a LightCycler (Roche, Mannheim, Germany) using Fast Start DNA Master SYBR Green I. The expression level of each gene was quantified using external standardized dilution, and normalized by 28S ribosomal RNA. Primer sequences are shown in Table 2. The specificity of the primers was confirmed by checking the product size and restriction enzyme pattern by gel electrophoresis and the melting temperature (data not shown).

Immunostaining

For tissue staining, frozen sections were fixed in 4% formaldehyde and incubated with a rabbit anti-Notch4 antibody (1:20, Santa Cruz Biotechnology, Santa Cruz, CA) or a rabbit anti-Ptgr1 antibody (1:20) which was a kind gift from Prof. Takao Shimizu (University of Tokyo) [42].

Abbreviations

BMMC: bone marrow-derived mast cell; CL: cluster; sMC: submucosa mast cell; DEPC: diethylpyrocarbonate; ECM: extracellular matrix; LCM: laser capture microdissection; LT: leukotriene; MC: mast cell; mMC: mucosa mast cell; PCA: principal component analysis; PG: prostaglandin; *r*: correlation coefficient; RMA: robust multi-array average; rRNA: ribosomal RNA; RT-PCR: reverse transcription-polymerase chain reaction.

Authors' contributions

ST designed the research, performed the research and wrote the paper; YT performed the research and wrote the paper; ES-N wrote the paper; YO performed the microar-

Table 2: List of primers used for real-time PCR analysis.

Gene Symbol	Forward primer (5' -> 3')	Reverse primer (5' -> 3')
<i>Kit</i>	ATAGACCCGACGCAAC	AATAAACGAGTCACGCT
<i>Fcer1a</i>	GCCCCGTCTCCATTAG	CAATAACCCCGTGTC
<i>Mcpt1</i>	AAACAGTCATAAATGGCAAG	GGGAACAAACCATCATCAC
<i>Mcpt2</i>	TTCATTGCCTAGTCTCTCT	CTTTTCAGCTACTTGCTCT
<i>Mcpt4</i>	CCTTACATGGCCCATCT	CTTCCCGGCTTGATA
<i>Cma2</i>	GCGGAAATGCAAAGCC	ACAGGGAACAGTCCATC
<i>Anxa10</i>	TACCCACAACCTTCGGC	GGCAAGTAGTGCTTTCT
<i>Ctse</i>	GCAAGCCTATTGGCAG	TGGCATCGTGTCCGAGA
<i>Fos</i>	TGTGTACTCCCGTGGT	ACGAACAGGTAAGGTCC
<i>Ptgr1</i>	CATCGTGAATCGGTGG	GCTAGGTCAAACGCAT
<i>Cnn1</i>	ACGGCCTACGGTACAC	GGTACTCCGGGTTGAG
<i>Ces3</i>	AGTGATTGTGTCTCGAAG	GTTCCCATTCGGAGCA
<i>Cpe</i>	ACCGGAAGAGACTCTCA	CCAGTAATCCCCATCCT
<i>Notch4</i>	CCCTTAAACTCGGTGT	GGTGCTTAATAAATAGTTGCC
28S rRNA	CAGTACGAATACAGACCG	GGCAACAACACATCATCAG

ray data and statistical analysis; ST performed the research; GT designed the research; ST performed the research; YS designed the research and wrote the paper. Conflict-of-interest: The authors declare no competing financial interests.

Additional material

Additional file 1

Genes with significantly different expression between sMCs and mMCs. The list represents 1,272 genes significantly altered between sMCs and mMCs in the order of clustering (Figure 5a). The values represent expression levels normalized to those of BMDCs.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2164-10-35-S1.xls>]

Acknowledgements

This work was supported by Grants-in-Aid for Scientific Research on Priority Areas "Applied Genomics" from the Ministry of Education, Science, Sports, and Culture of Japan and from the Ministry of Health and Labor of Japan. We thank Dr. K Nakayama (Kyoto University) for their invaluable advice on this study. We appreciate Drs. T Shimizu and T Yokomizo for providing an anti-Ptgr1 antibody and generous instructions. We also thank Dr. HA Popiel and Ms. Y Nakaminami for careful reading and secretary assistance, respectively.

References

1. Metcalfe DD, Baram D, Mekori YA: **Mast cells.** *Physiol Rev* 1997, **77**:1033-1079.
2. Reynolds DS, Stevens RL, Lane WS, Carr MH, Austen KF, Serafin WE: **Different mouse mast cell populations express various combinations of at least six distinct mast cell serine proteases.** *Proc Natl Acad Sci USA* 1990, **87**:3230-3234.
3. Bradding P, Okayama Y, Kambe N, Saito H: **Ion channel gene expression in human lung, skin, and cord blood-derived mast cells.** *J Leukoc Biol* 2003, **73**:614-620.
4. Ogasawara T, Murakami M, Suzuki-Nishimura T, Uchida MK, Kudo I: **Mouse bone marrow-derived mast cells undergo exocytosis, prostanoid generation, and cytokine expression in response to G protein-activating polybasic compounds after coculture with fibroblasts in the presence of c-kit ligand.** *J Immunol* 1997, **158**:393-404.
5. Hernandez-Hansen V, Bard JD, Tarleton CA, Wilder JA, Lowell CA, Wilson BS, Oliver JM: **Increased expression of genes linked to FcepsilonRI Signaling and to cytokine and chemokine production in Lyn-deficient mast cells.** *J Immunol* 2005, **175**:7880-7888.
6. Iida M, Matsumoto K, Tomita H, Nakajima T, Akasawa A, Ohtani NY, Yoshida NL, Matsui K, Nakada A, Sugita Y, Shimizu Y, Wakahara S, Nakao T, Fujii Y, Ra C, Saito H: **Selective down-regulation of high-affinity IgE receptor (FcepsilonRI) alpha-chain messenger RNA among transcriptome in cord blood-derived versus adult peripheral blood-derived cultured human mast cells.** *Blood* 2001, **97**:1016-1022.
7. Nakajima T, Matsumoto K, Suto H, Tanaka K, Ebisawa M, Tomita H, Yuki K, Katsunuma T, Akasawa A, Hashida R, Sugita Y, Ogawa H, Ra C, Saito H: **Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays: abundant expression of major basic protein in mast cells.** *Blood* 2001, **98**:1127-1134.
8. Babina M, Schulke Y, Kirchhof L, Guhl S, Franke R, Bohm S, Zuberbier T, Henz BM, Gombart AF: **The transcription factor profile of human mast cells in comparison with monocytes and granulocytes.** *Cell Mol Life Sci* 2005, **62**:214-226.
9. Inomata N, Tomita H, Ikezawa Z, Saito H: **Differential gene expression profile between cord blood progenitor-derived and adult progenitor-derived human mast cells.** *Immunol Lett* 2005, **98**:265-271.
10. Okumura S, Kashiwakura J, Tomita H, Matsumoto K, Nakajima T, Saito H, Okayama Y: **Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FcepsilonRI.** *Blood* 2003, **102**:2547-2554.
11. Enerback L: **Mast cells in rat gastrointestinal mucosa. 2. Dye-binding and metachromatic properties.** *Acta Pathol Microbiol Scand* 1966, **66**:303-312.
12. Friend DS, Ghildyal N, Austen KF, Gurish MF, Matsumoto R, Stevens RL: **Mast cells that reside at different locations in the jejunum of mice infected with *Trichinella spiralis* exhibit sequential changes in their granule ultrastructure and chymase phenotype.** *J Cell Biol* 1996, **135**:279-290.
13. Knight PA, Wright SH, Lawrence CE, Paterson YY, Miller HR: **Delayed expulsion of the nematode *Trichinella spiralis* in mice lacking the mucosal mast cell-specific granule chymase, mouse mast cell protease-1.** *J Exp Med* 2000, **192**:1849-1856.
14. Chu W, Johnson DA, Musich PR: **Molecular cloning and characterization of mouse mast cell chymases.** *Biochim Biophys Acta* 1992, **1121**:83-87.
15. Qiu FH, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH, Besmer P: **Primary structure of c-kit: relationship with the CSF-1I**

- PDGF receptor kinase family – oncogenic activation of v-kit involves deletion of extracellular domain and C terminus.** *EMBO J* 1988, **7**:1003-1011.
16. Ra C, Jouvin MH, Kinet JP: **Complete structure of the mouse mast cell receptor for IgE (Fc epsilon RI) and surface expression of chimeric receptors (rat-mouse-human) on transfected cells.** *J Biol Chem* 1989, **264**:15323-15327.
 17. Ghildyal N, McNeil HP, Stechschulte S, Austen KF, Silberstein D, Gurish MF, Somerville LL, Stevens RL: **IL-10 induces transcription of the gene for mouse mast cell protease-1, a serine protease preferentially expressed in mucosal mast cells of Trichinella spiralis-infected mice.** *J Immunol* 1992, **149**:2123-2129.
 18. Trong HL, Newlands GF, Miller HR, Charbonneau H, Neurath H, Woodbury RG: **Amino acid sequence of a mouse mucosal mast cell protease.** *Biochemistry* 1989, **28**:391-395.
 19. Serafin WE, Reynolds DS, Rogel S, Lane WS, Conder GA, Johnson SS, Austen KF, Stevens RL: **Identification and molecular cloning of a novel mouse mucosal mast cell serine protease.** *J Biol Chem* 1990, **265**:423-429.
 20. Serafin WE, Sullivan TP, Conder GA, Ebrahimi A, Marcham P, Johnson SS, Austen KF, Reynolds DS: **Cloning of the cDNA and gene for mouse mast cell protease 4. Demonstration of its late transcription in mast cell subclasses and analysis of its homology to subclass-specific neutral proteases of the mouse and rat.** *J Biol Chem* 1991, **266**:1934-1941.
 21. Morgan RO, Jenkins NA, Gilbert DJ, Copeland NG, Balsara BR, Testa JR, Fernandez MP: **Novel human and mouse annexin A10 are linked to the genome duplications during early chordate evolution.** *Genomics* 1999, **60**:40-49.
 22. Tatnell PJ, Lees WE, Kay J: **Cloning, expression and characterization of murine procathepsin E.** *FEBS Lett* 1997, **408**:62-66.
 23. Curran T, MacConnell WP, van Straaten F, Verma IM: **Structure of the FBJ murine osteosarcoma virus genome: molecular cloning of its associated helper virus and the cellular homolog of the v-fos gene from mouse and human cells.** *Mol Cell Biol* 1983, **3**:914-921.
 24. Yokomizo T, Izumi T, Takahashi T, Kasama T, Kobayashi Y, Sato F, Taketani Y, Shimizu T: **Enzymatic inactivation of leukotriene B4 by a novel enzyme found in the porcine kidney. Purification and properties of leukotriene B4 12-hydroxydehydrogenase.** *J Biol Chem* 1993, **268**:18128-18135.
 25. Strasser P, Gimona M, Moessler H, Herzog M, Small JV: **Mammalian calponin. Identification and expression of genetic variants.** *FEBS Lett* 1993, **330**:13-18.
 26. Ovnich M, Tepperman K, Medda S, Elliott RW, Stephenson DA, Grant SG, Ganschow RE: **Characterization of a murine cDNA encoding a member of the carboxylesterase multigene family.** *Genomics* 1991, **9**:344-354.
 27. Fricker LD, Evans CJ, Esch FS, Herbert E: **Cloning and sequence analysis of cDNA for bovine carboxypeptidase E.** *Nature* 1986, **323**:461-464.
 28. Uyttendaele H, Marazzi G, Wu G, Yan Q, Sassoon D, Kitajewski J: **Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene.** *Development* 1996, **122**:2251-2259.
 29. Hassouna N, Michot B, Bachelier JP: **The complete nucleotide sequence of mouse 28S rRNA gene. Implications for the process of size increase of the large subunit rRNA in higher eukaryotes.** *Nucleic Acids Res* 1984, **12**:3563-3583.
 30. Radtke F, Wilson A, Mancini SJ, MacDonald HR: **Notch regulation of lymphocyte development and function.** *Nat Immunol* 2004, **5**:247-253.
 31. Sakata-Yanagimoto M, Nakagami-Yamaguchi E, Saito T, Kumano K, Yasutomo K, Ogawa S, Kurokawa M, Chiba S: **Coordinate regulation of transcription factors through Notch2 is an important mediator of mast cell fate.** *Proc Natl Acad Sci USA* 2008, **105**:7839-7844.
 32. Vercauteren SM, Sutherland HJ: **Constitutively active Notch4 promotes early human hematopoietic progenitor cell maintenance while inhibiting differentiation and causes lymphoid abnormalities in vivo.** *Blood* 2004, **104**:2315-2322.
 33. Nickoloff BJ, Qin JZ, Chaturvedi V, Denning MF, Bonish B, Miele L: **Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma.** *Cell Death Differ* 2002, **9**:842-855.
 34. Hori T, Yokomizo T, Ago H, Sugahara M, Ueno G, Yamamoto M, Kumasaka T, Shimizu T, Miyano M: **Structural basis of leukotriene B4 12-hydroxydehydrogenase/15-Oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop.** *J Biol Chem* 2004, **279**:22615-22623.
 35. Brennan D, Hu Y, Kljuic A, Choi Y, Joubert S, Bashkin M, Wahl J, Fertala A, Pulkkinen L, Uitto J, Christiano AM, Panteleyev A, Mahoney MG: **Differential structural properties and expression patterns suggest functional significance for multiple mouse desmoglein 1 isoforms.** *Differentiation* 2004, **72**:434-449.
 36. Vodenicharov A, Chouckov C: **Morphological study of mast cell localization in the wall of the proximal tubule in the domestic swine kidney.** *Anat Histol Embryol* 1999, **28**:85-88.
 37. Swart GW, Lunter PC, Kilsdonk JW, Kempen LC: **Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration?** *Cancer Metastasis Rev* 2005, **24**:223-236.
 38. Cook-Mills JM: **VCAM-1 signals during lymphocyte migration: role of reactive oxygen species.** *Mol Immunol* 2002, **39**:499-508.
 39. Tanaka S, Takasu Y, Mikura S, Satoh N, Ichikawa A: **Antigen-independent induction of histamine synthesis by immunoglobulin E in mouse bone marrow-derived mast cells.** *J Exp Med* 2002, **196**:229-235.
 40. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: **Summaries of Affymetrix GeneChip probe level data.** *Nucleic Acids Res* 2003, **31**:e15.
 41. Sugimoto Y, Tsuboi H, Okuno Y, Tamba S, Tsuchiya S, Tsujimoto G, Ichikawa A: **Microarray evaluation of EP4 receptor-mediated prostaglandin E2 suppression of 3T3-L1 adipocyte differentiation.** *Biochem Biophys Res Commun* 2004, **322**:911-917.
 42. Yamamoto T, Yokomizo T, Nakao A, Izumi T, Shimizu T: **Immunohistochemical localization of guinea-pig leukotriene B4 12-hydroxydehydrogenase/15-keto prostaglandin 13-reductase.** *Eur J Biochem* 2001, **268**:6105-6113.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp



Global correlation analysis for micro-RNA and mRNA expression profiles in human cell lines

Yoshinao Ruike · Atsuhiko Ichimura · Soken Tsuchiya · Kazuharu Shimizu · Ryo Kunimoto · Yasushi Okuno · Gozoh Tsujimoto

Received: 19 February 2008 / Accepted: 29 February 2008 / Published online: 10 May 2008
© The Japan Society of Human Genetics and Springer 2008

Abstract Microribonucleic acids (miRNAs) are small noncoding RNAs that negatively regulate gene expression at the posttranscriptional level. Although considerable progress has been made in studying the function of miRNAs, they still remain largely unclear, mainly because of the difficulty in identifying target genes for miRNA. We performed a global analysis of both miRNAs and mRNAs expression across 16 human cell lines and extracted negatively correlated pairs of miRNA and mRNA which indicate miRNA-target relationship. The many of known-target of *miR-124a* showed negative correlation, suggesting our analysis were valid. We further extracted physically relevant miRNA-target gene pairs, applying computational target prediction algorithm with inverse correlations of miRNA and messenger RNA (mRNA) expression. Furthermore, gene-ontology-based annotation and functional enrichment analysis of the extracted miRNA-target gene

pairs made it possible to indicate putative functions of miRNAs. The data collected here will be of value for further studies into the function of miRNA.

Keywords Micro-RNA · Microarray · Transcriptome · Correlation analysis · GO analysis

Introduction

Microribonucleic acids (miRNAs) are a class of small (approximately 22 nucleotides) noncoding RNAs that negatively regulate gene expression at the posttranscriptional level. They play profound and pervasive roles in manipulating gene expression involved in cell development, proliferation and apoptosis in various eukaryotes (Sevignani et al. 2006). Also, recent evidence indicated that aberrant miRNA expression in the pathogenesis of several human diseases (van Rooij et al. 2006; Takamizawa et al. 2004; Iorio et al. 2005), revealing that miRNA genes could be a potential target for drug discovery (Sevignani et al. 2006; Liu et al. 2007; Tsuchiya et al. 2006).

In the past few years, several hundred miRNAs were identified in animals and plants, although it is estimated that miRNAs account for ~1% of predicted genes in higher eukaryotic genomes (Griffiths-Jones 2004). Only a handful of miRNA, however, have been functionally characterized. These findings, together with the complicated expression patterns and large number of predicted targets, imply that miRNAs may regulate a broad range of physiological and developmental process.

Identifying targets of each miRNA is crucial for understanding the biological functions of miRNAs, as miRNA-directed regulation occurs at a posttranscriptional level via interaction with their target messenger RNA (mRNA)

Electronic supplementary material The online version of this article (doi:10.1007/s10038-008-0279-x) contains supplementary material, which is available to authorized users.

Y. Ruike · A. Ichimura · R. Kunimoto · G. Tsujimoto (✉)
Department of Genomic Drug Discovery Science,
Graduate School of Pharmaceutical Sciences,
Kyoto University, 46-29 Yoshida Shimoauchi-cho Sakyo-ku,
Kyoto 606-8501, Japan
e-mail: gtsuji@pharm.kyoto-u.ac.jp

S. Tsuchiya · K. Shimizu
Department of Nanobio Drug Discovery,
Graduate School of Pharmaceutical Sciences,
Kyoto University, Kyoto, Japan

Y. Okuno
Department of Pharmacoinformatics,
Graduate School of Pharmaceutical Sciences,
Kyoto University, Kyoto, Japan

to elicit degradation or translational repression of complementary mRNA targets (Behm-Ansmant et al. 2006; Chendrimada et al. 2007). Also, miRNAs are known to be only partially complementary to their targets and can induce significant degradation of many mRNA targets in animals (Bagga et al. 2005; Jing et al. 2005; Giraldez et al. 2006; Rehwinkel et al. 2006). This ambiguity makes it difficult to predict the targets of miRNAs [up to 30% of genes have been predicted to be regulated by miRNAs (Lewis et al. 2003)]. However, most of the predicted miRNA-target pairs remain to be biologically verified, because a simple, high throughput method to biologically validate miRNA-targets does not exist. Several recent studies revealed spatial or temporal avoidance of miRNA coexpression with target genes (Farh et al. 2005; Sood et al. 2006). Thus, genes preferentially expressed at the same time and place as an miRNA have evolved to selectively avoid sites matching the miRNA (Farh et al. 2005). These findings may support the negative correlation between miRNA and their target mRNA expression level as a whole. Based on the idea that negative correlation between miRNA and mRNA expression levels may reflect miRNA-target relationship, we performed a global analysis of both miRNA and mRNA expression across 16 human cell lines. Global correlation analysis of the expression profiles collected revealed a useful approach to identify the miRNA-target interactions.

Materials and methods

Cell lines and RNA purification

We used 16 well-studied, various organ-derived cell lines in this study: human lung carcinoma A549 (Giard et al. 1973), fibrosarcoma HT1080 (Rasheed et al. 1974), cervix carcinoma Henrietta Lacks (HeLa) (Scherer et al. 1953), cervix carcinoma HeLaS3 (subclone of HeLa) (Puck et al. 1956), hepatocellular carcinoma Huh7 (Nakabayashi et al. 1985), breast adenocarcinoma MCF7 (Soule et al. 1973), breast adenocarcinoma MDAMB231 (Cailleau et al. 1974), embryonal kidney HEK293T (subclone of HEK293) (Dunbridge et al. 1987), colon adenocarcinoma HT29 (Fogh et al. 1977), hepatocellular carcinoma HepG2 (Aden et al. 1979), neuroblastoma SKNSC (Biedler et al. 1973), colon adenocarcinoma Caco₂ (Fogh et al. 1977), embryonal kidney HEK293 (Graham et al. 1977), and colon carcinoma HCT116 (Brattain et al. 1981). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). Human T-cell leukemia Jurkat (Schneider et al. 1977) and chronic myeloid leukemia K562 (Lozzio and Lozzio 1973) cell lines were cultured in Roswell Park Memorial Institute (RPMI) medium containing 10% FBS. Exponentially growing cells

were harvested, and total RNA was collected by standard procedures using ISOGEN (Nippon Gene) and chloroform and precipitated with isopropanol. Integrity and purity of RNA was verified with an Agilent Bioanalyzer.

Quantification of miRNAs using stem-loop real-time PCR

Expression of 148 miRNAs was measured by reverse transcription followed by the real-time polymerase chain reaction (RT-PCR) assay as previously described (Gaur et al. 2007). This method uses stem-loop primers for reverse transcription followed by RT-PCR (TaqMan MicroRNA Assays; Applied Biosystems). ABI PRISMTM 7700 Sequence Detector was used to detect amplification. This stem-loop RT-PCR method detects specifically mature, but not precursor, miRNA. RNA input was normalized by measuring U6 expression using the following TaqMan probes.

5'-FAM-CCCCTGCGCAAGGA-MGB3', forward primer: 5'-TGGAACGATACAGAGAAGATTAGCA-3', reverse primer: 5'-AACGCTTCACGAATTTGCGT-3'. Expression data of a few miRNA was confirmed to be well correlated to those obtained by Northern analysis (data not shown).

Microarray experiments

Genome-wide mRNA expression profiles of 16 human cell lines were obtained by microarray analysis with the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array, according to the manufacturer's instructions. Briefly, double-stranded complementary DNA (cDNA) was synthesized from total RNA. An in vitro transcription reaction was then carried out to produce biotin-labeled complementary RNA (cRNA) from the cDNA. The cRNA was then fragmented and used for hybridization. The hybridized probe array was subsequently stained and scanned by a Genechip Scanner 3000. We used the robust multiarray analysis (RMA) expression measure that represents the log transform of (background corrected and normalized) intensities of the GeneChips (Gautier et al. 2004). RMA measures were computed using the R package program (<http://www.bioconductor.org>). The probe sets with the lowest maximal expression across the samples in the data set (30%) were removed.

Data analysis

Experimentally normalized Δ Ct values for the miRNA profiles, or normalized microarray data sets for mRNA profiles, were used to classify cells by agglomerative hierarchical clustering based on Euclidean distances between data sets. The Δ Ct values for the miRNA profiles

were used to evaluate the 16 cell lines by agglomerative hierarchical clustering using average linkage and correlation similarity and verified for significance by multiscale bootstrap resampling analysis (Suzuki and Shimodaira 2006). Classical Pearson's correlation tests were performed to verify the relationships between expression profiles of miRNA and mRNA. The significance of each correlation was assessed by assuming that the distribution of correlations under the null hypothesis of no correlation follows a t distribution with $n - 2$ degrees of freedom, where n is the number of measurements in the expression profile.

Target prediction and GO term enrichment analysis

Potential targets for miRNAs were predicted among 3' untranslated region (UTR) sequences of inversely correlated target transcripts using the miRanda algorithm, which is associated with the Sanger MIRBASE (Enright et al. 2003). algorithm parameters were set as follows: score threshold at 50, energy threshold at -20 kcal/mol, scaling parameter at 4, gap-open penalty at -2 , and gap-extend penalty at -8 . The significance of enrichment of a list of target genes with genes belonging to a gene ontology (GO) group were scored using weight algorithm (Ashburner et al. 2000; Alexa et al. 2006). The algorithm for GO group scoring was implemented in the R programming language. The results were obtained using R version 2.5.0 and the libraries provided by the Bioconductor project, version 1.14 (Gentleman et al. 2004).

Results

Micro-RNA expression profiles in 16 human cell lines

We performed quantitative measurement of 155 kinds of mature human miRNAs in 16 human cell lines. The probe sets for miRNA with minimal Ct values >35 in all cell lines were excluded from the following analysis. Seven miRNAs were thus excluded, and the remaining 148 different mature miRNAs were used for further analysis (expression data in a text format is provided in Table S1).

To characterize the expression patterns of miRNAs, hierarchical clustering was performed using normalized Δ Ct values (Fig. 1). The most prominent feature of the clustered data was that many miRNAs displayed similar expression pattern among the majority of samples, although some miRNAs displayed very specific expression patterns. Hierarchical clustering of 16 cell lines resulted in a dendrogram, which contained small clusters reflecting common tissue origin (e.g., HepG2 and Huh7) or subclones


(e.g., HeLa and HeLaS3). We also found some cell lines showed characteristic expression patterns independent of their tissue origins. In particular, Caco₂ had a very different expression pattern from HT-29 or HCT-116, although all of them originated from colon carcinoma. Thus, some miRNAs were specifically expressed in Caco₂ (e.g., miR-372 and -373), but not in either HT-29 or HCT-116. Determining the differential expression of miRNAs from similar biological backgrounds would be of value to investigate the functions of miRNA.

To classify expression patterns of miRNAs, we employed hierarchical clustering based on correlation similarity between each miRNA (Fig. 2). This analysis revealed the relationships between miRNAs that had similar expression patterns among cell lines. To assess the robustness of these relationships, we conducted a multiscale bootstrap resampling analysis (Suzuki and Shimodaira 2006) and verified the significance (Fig. 2). The resulting dendrogram had several statistically significant clusters of miRNAs, suggesting that their expression might be commonly regulated. Noticeably, many miRNAs that coexpressed formed genomic clusters. Frequent coexpression between neighboring miRNAs that formed genomic clusters were previously reported, analyzing miRNA expression patterns across 24 normal human organs (Baskerville and Bartel 2005). To test coexpression between neighboring miRNAs, we examined the relationship between genomic distance and correlation coefficients between neighboring miRNAs. Among the miRNAs measured, miRNAs with several genomic origins, which can be indicated by the presence of multiple premature miRNA, were excluded in the following analysis. Micro-RNAs from the same chromosome and oriented in the same direction were defined as "paired". For the resulting 224 pairs (miRNA pairs are summarized in Table S2), we examined the relationship between the genomic distance of each miRNA pair and the correlation coefficient of the miRNA expression pattern (Fig. 3). Most pairs of miRNAs separated by <100 kb showed highly positive correlation.

Genome-wide gene expression analysis

Next, we obtained a global gene expression profile by employing microarray analysis using the same RNA samples used for quantifying miRNA (microarray data was deposited in Gene Expression Omnibus accession number GSE10021). The miRNAs located in the intronic region of genes are usually coordinately expressed with their host gene mRNA (Baskerville and Bartel 2005). Among 148 miRNAs measured in this study, 40 were derived from the intronic region of genes and examined for their correlation with the corresponding host genes

Fig. 1 Hierarchical clustering of 148 microribonucleic acid (miRNA) expression profiles in 16 human cell lines. Expression profiles (Δ Ct values) of 148 miRNAs measured in total RNA from cell lines were clustered






Fig. 2 Hierarchical clustering with bootstrap analysis based on correlational expression profiles among 148 microribonucleic acids (miRNAs). Expression profiles of 148 miRNAs were clustered and verified for significance by multiscale bootstrap resampling analysis (1,000 iterations, sampling with replacement). Clusters were scored as statistically significant in cases in which miRNAs clustered with a 99% or better confidence interval (corresponding to $p < 0.01$), as determined by the bootstrap analysis

using standard Pearson's correlation test (Table 1). The strong correlation between intronic miRNA and host genes was observed, suggesting they are derived from the same precursor genes, which might be under the control of the same promoter.

To determine whether the negative correlation observed between miRNA and gene expression reflected miRNA-target gene relationships, we first examined the relationship using a previously identified miRNA-target gene pairs. We examined *miR-124a*, which has the largest number of known target genes (Lim et al. 2005), as a control. The *miR-124a* expression level measured by RT-PCR analysis was compared with either those of the known target genes or those of all genes, both obtained by microarray analysis in 16 cell lines. Then, each data set was subjected to Pearson's correlation test (Fig. 4). The distribution of correlation coefficient for *miR-124a*-target gene pairs was shifted toward negative side, compared to that of the *miR-124a*-total gene pairs. The mean of correlation coefficients between the two sets was significantly different ($p < 0.01$). Furthermore, Fisher's exact test showed a significant accumulation of target genes





Fig. 3 Relationship between the distance separating miRNA (miRNA) loci and their coordinate expression in human tissues. Each miRNA was paired with each of the others lying in the same orientation on the same chromosome. For each pair, the correlation coefficient for their expression was plotted according to the distance between the two loci (white circle)

Table 1 Correlation of intronic microribonucleic acid (miRNA) expression with host gene expression

Host gene	RefSeq ID	miRNA	Correlation
MEST	NM_002402	hsa-mir-335	0.92
C9orf3	NM_032823	hsa-mir-23b	0.86
EVL	NM_016337	hsa-mir-342	0.84
C9orf3	NM_032823	hsa-mir-27b	0.83
PTK2	NM_005607	hsa-mir-151	0.82
240284_x_at	–	hsa-mir-141	0.80
GABRE	NM_004961	hsa-mir-224	0.78
RNF130	NM_018434	hsa-mir-340	0.77
EGFL7	NM_016215	hsa-mir-126	0.76
LPP	NM_005578	hsa-mir-28	0.72
229934_at	–	hsa-mir-223	0.70
1554097_a_at	–	hsa-mir-31	0.67
ZNF265	NM_005455	hsa-mir-186	0.66
FAM33A	NM_182620	hsa-mir-301	0.66
EML2	NM_012155	hsa-mir-330	0.60
1558515_at	–	hsa-mir-374	0.60
GPC1	NM_002081	hsa-mir-149	0.59
MGC11257	NM_032350	hsa-mir-339	0.59
C9orf3	NM_032823	hsa-mir-189	0.59
ARPP-21	NM_001025068	hsa-mir-128b	0.58
BIC	NR_001458	hsa-mir-155	0.58
240284_x_at	–	hsa-mir-200c	0.56
AATK	XM_927215	hsa-mir-338	0.54
FSTL1	NM_007085	hsa-mir-198	0.53
SMC4L1	NM_001002799	hsa-mir-15b	0.52
CTDSP1	NM_021198	hsa-mir-26b	0.50
MCM7	NM_005916	hsa-mir-25	0.50
MEG3	NR_002766	hsa-mir-127	0.45
ARRB1	NM_004041	hsa-mir-326	0.39
PDE2A	NM_002599	hsa-mir-139	0.26
TMEM113	NM_025222	hsa-let-7g	0.26
228528_at	–	hsa-mir-29c	0.21
WWP2	NM_007014	hsa-mir-140	0.19
TLN2	NM_015059	hsa-mir-190	0.16
R3HDM1	NM_015361	hsa-mir-128a	0.15
TRPM3	NM_001007470	hsa-mir-204	0.00
COPZ2	NM_016429	hsa-mir-152	-0.10
PANK1	NM_138316	hsa-mir-107	-0.14
DLEU2	NR_002612	hsa-mir-15a	-0.17
C21orf34	NM_001005732	hsa-mir-99a	-0.38

Gene symbol of the host gene, RefSeq ID, intronic miRNA, and correlation coefficient are listed for each intronic miRNA host gene pairs

within the inversely correlated group of genes [odds ratio (OR) 2.5, $p < 0.01$], indicating that the negative correlation observed between miRNA and gene expression in this reflects miRNA-target gene relationship.

**Fig. 4** Distribution of correlation coefficients between *miR-124a* and known targets of *miR-124a*. The estimated densities of distributions for target genes (red) or total genes (black) were plotted

To extract a global relationship of miRNA-target genes, all miRNA-mRNA pairs were subjected to Pearson's correlation test. Of the total 5.7 million different pairs examined, 184,901 miRNA-mRNA pairs (3.2%) showed a negative correlation.

Applying miRNA-target prediction algorithm

Because negative correlation might also reflect indirect regulation of gene expression by miRNAs, we further examined whether the extracted genes contained the corresponding target sites for miRNA in the 3' UTRs. To seek miRNA-directed target sites, we adopted the miRanda algorithm (Enright et al. 2003) to a set of 30,664 different transcripts enrolled in RefSeq and monitored them by microarray. This analysis yielded 44,572 miRNA-target gene pairs that fulfilled the conditions that the expression level of genes negatively correlated with that of the miRNA, and that the genes contain the target sequence against the miRNA. Hence, approximately 300 genes per miRNA were extracted on average. Based on the extracted miRNA-target gene pairs, we next tried to predict the functions of miRNA. Thus, we calculated the frequency of gene ontology (GO) term (biological process area) of target genes for each miRNA. The GO terms were chosen if the frequency of the GO term was statistically significantly more than that expected by chance. Table 2 lists the top 30 miRNAs that had the highest GO term frequency. Most miRNA-target gene pairs were found to be novel, and the frequently noted GO terms for each miRNA was a diverse and wide variety in the biological process.

Table 2 Gene ontology (GO) term enrichment analysis for predicted microribonucleic acid (miRNA)-target genes

GO ID	Number of categorized genes	Number of extracted genes	Number of expected genes	<i>P</i> value (weight algorithm)	miRNA	GO definition
GO:0006694	139	10	1.1	1.70E-07	hsa-mir-320	Steroid biosynthesis
GO:0006694	139	8	0.79	1.30E-06	hsa-mir-34c	Steroid biosynthesis
GO:0016125	158	9	1.19	3.20E-06	hsa-mir-34b	Sterol metabolism
GO:0030001	663	27	10.95	1.80E-05	hsa-mir-331	Metal ion transport
GO:0006955	991	42	19.2	2.00E-05	hsa-mir-296	Immune response
GO:0045086	19	5	0.36	2.20E-05	hsa-mir-34a	Positive regulation of interleukin-2 biosynthesis
GO:0046321	9	3	0.06	2.40E-05	hsa-mir-99a	Positive regulation of fatty acid oxidation
GO:0015808	4	2	0.01	3.60E-05	hsa-mir-195	L-alanine transport
GO:0001568	369	12	2.95	4.50E-05	hsa-mir-150	Blood-vessel development
GO:0001678	4	2	0.01	7.10E-05	hsa-mir-16	Cell glucose homeostasis
GO:0042104	12	4	0.25	8.20E-05	hsa-mir-324-5p	Positive regulation of activated T-cell proliferation
GO:0016125	158	5	0.44	8.40E-05	hsa-mir-152	Sterol metabolism
GO:0006694	139	7	1.04	8.90E-05	hsa-mir-34b	Steroid biosynthesis
GO:0051085	19	4	0.25	9.70E-05	hsa-mir-133a	Chaperone cofactor-dependent protein folding
GO:0007588	78	9	1.92	0.00013	hsa-mir-328	Excretion
GO:0046006	16	4	0.3	0.00018	hsa-mir-149	Regulation of activated T-cell proliferation
GO:0045471	4	2	0.02	0.00019	hsa-mir-148a	Response to ethanol
GO:0006355	4315	42	24.64	0.00019	hsa-mir-31	Regulation of transcription, DNA dependent
GO:0006955	991	29	13.02	0.00022	hsa-mir-133a	Immune response
GO:0006656	14	2	0.02	0.00026	hsa-mir-368	Phosphatidylcholine biosynthesis
GO:0042552	44	2	0.03	0.00028	hsa-mir-29c	Myelination
GO:0030001	663	33	16.34	0.0003	hsa-mir-328	Metal ion transport
GO:0042104	12	3	0.14	0.00032	hsa-mir-181b	Positive regulation of activated T-cell proliferation
GO:0006825	16	3	0.14	0.00033	hsa-let-7i	Copper ion transport
GO:0006857	14	3	0.14	0.00033	hsa-mir-122a	Oligopeptide transport
GO:0006611	54	3	0.13	0.00033	hsa-mir-21	Protein export from nucleus
GO:0006825	16	3	0.14	0.00034	hsa-mir-132	Copper ion transport
GO:0030041	71	4	0.33	0.00035	hsa-mir-154	Actin filament polymerization
GO:0006235	3	2	0.03	0.00035	hsa-mir-27b	dTTP biosynthesis
GO:0006011	4	2	0.03	0.00035	hsa-mir-325	UDP-glucose metabolism

Top 30 highly enriched GO terms. *P* values were calculated using weight algorithm

Discussion

To investigate biological functions of miRNA, it is critical to identify miRNA-directed target genes. However, currently available computational methods (e.g., miRanda, PicTar, and TargetScan) predict numerous target genes that contain many false positives for miRNA (Mazière and Enright 2007). Also, experimental verification of miRNA-target relationship is complicated by

the potential outcome of such an interaction being either translational repression or degradation. Furthermore, miRNAs can target multiple genes, and thereby the biological function of a single miRNA can be diverse. Hence, not only to achieve a higher degree of specificity of the prediction (few false positives) but also to comprehensively understand the function of miRNA, large-scale prediction of targets across a whole genome would be required.

In this study, we intended to investigate global miRNA-target relationships, assuming a negative correlation between miRNA and gene expression levels as an indicator for the miRNA-target relationship. The collected genome-wide expression data sets of both miRNA and mRNA enabled global correlation analysis between a miRNA and its target gene. Based on the observation that the expression of genes known as *miR-124a* targets tended to be negatively correlated with *miR-124a* expression, we reasoned that correlation analysis would be useful in investigating miRNA-target relationship. Then, we further extracted miRNA-target gene pairs by collecting genes that contain miRNA-directed target sites within 3' UTR. The resulting list of miRNA gene pairs may provide useful information in investigating miRNA-target relationship.

Our miRNA-expression study provides important information on endogenous miRNA expression in 16 cell lines. One of the most serious problems in exploring miRNA function in a cell-based assay is the influence of endogenous miRNA expression. For example, in vitro reporter gene assay, a general approach used for target gene validation, has different results in different cell lines examined. This is thought to be due to the differential expression of endogenous miRNAs in the cell line used, as it strongly affects background expression of the reporter gene containing the test sequence. As we examined genetically tractable and well-studied cell lines in this study, the data obtained should be informative for studying functions of miRNA using those cell lines.

In collecting global miRNA and gene-expression profiles, we observed that many of the neighboring miRNA pairs, which were located within ~100-kb region of the chromosome, showed a significantly positive correlation and that the expression of intronic miRNAs was generally correlated with that of host genes. These results were consistent with the idea that clustered miRNAs are processed from the same primary transcript (Suh et al. 2004) and that intronic miRNAs are from the same primary transcript as their host gene (Lau et al. 2001; Sempere et al. 2004). Unexpectedly, however, we observed that miRNAs expressed from the same miRNA precursor (ex, *miR-142-3p* and *-5p*) were not coexpressed. This discrepancy could be explained by the fact that expression of these miRNAs depends on asymmetric selection of mature miRNA strand followed by the cleavage of pre-miRNA (Hutvagner 2005). Although it likely involves differential binding to and then differential retention of the two individual RNA strands by Dicer and its associated proteins (Zeng 2006), the detailed molecular mechanism for this asymmetry is not clear. The differential expression among cell lines we studied may provide a clue to the mechanism of asymmetric selectivity.

Correlated expression of miRNA and corresponding genes may imply their association in function as well. GO-based annotation and functional enrichment analysis of the extracted miRNA-target gene pairs made it possible to indicate putative functions of miRNAs. The approach developed in this study should be of value for future studies into the functions of miRNAs.

Acknowledgments This work was supported in part by research grants from the Scientific Fund of the Ministry of Education, Science, and Culture of Japan (to GT); National Institute of Biomedical Innovation (to GT); the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO) (to GT); the Japan Health Science Foundation and the Ministry of Human Health and Welfare (to GT); and the 21st Century Center of Excellence Program "Knowledge Information Infrastructure for Genome Science" (to GT and YR). YR is supported as a Research Assistant by 21st Century COE program "Knowledge Information Infrastructure for Genome Science".

References

- Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB (1979) Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. *Nature* 282:615–616
- Alexa A, Rahnenführer J, Lengauer T (2006) Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. *Bioinformatics* 22:1600–1607
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: tool for the unification of biology. The gene ontology consortium. *Nat Genet* 25:25–29
- Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE (2005) Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. *Cell* 122: 553–563
- Baskerville S, Bartel DP (2005) Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. *RNA* 11:241–247
- Behm-Ansmant I, Rehwinkel J, Doerks T, Stark A, Bork P, Izaurralde E (2006) mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. *Genes Dev* 20:1885–1898
- Biedler JL, Helson L, Spengler BA (1973) Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. *Cancer Res* 33:2643–2652
- Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE (1981) Heterogeneity of malignant cells from a human colonic carcinoma. *Cancer Res* 41:1751–1756
- Cailleau R, Young R, Olivé M, Reeves WJ (1974) Breast tumor cell lines from pleural effusions. *J Natl Cancer Inst* 53:661–674
- Chendrimada TP, Finn KJ, Ji X, Baillyat D, Gregory RI, Liebhaber SA, Pasquinelli AE, Shiekhattar R (2007) MicroRNA silencing through RISC recruitment of eIF6. *Nature* 447:823–828
- DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. *Mol Cell Biol* 7:379–387
- Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS (2003) MicroRNA targets in *Drosophila*. *Genome Biol* 5:R1
- Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, Bartel DP (2005) The widespread impact of mammalian

- MicroRNAs on mRNA repression and evolution. *Science* 310:1817–1821
- Fogh J, Wright WC, Loveless JD (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. *J Natl Cancer Inst* 58:209–214
- Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. *Cancer Res* 67:2456–2468
- Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) Affy-analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics* 20:307–315
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornil K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* 5:R80
- Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. *J Natl Cancer Inst* 51:1417–1423
- Giraldez AJ, Mishima Y, Rihel J, Grocock RJ, VanDongen S, Inoue K, Enright AJ, Schier AF (2006) Zebrafish miR-430 promotes deadenylation and clearance of maternal mRNAs. *Science* 312:75–79
- Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J Gen Virol* 36:59–74
- Griffiths-Jones S (2004) The microRNA registry. *Nucleic Acids Res* 32:D109–D111
- Hutvagner G (2005) Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation. *FEBS Lett* 579:5850–5857
- Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. *Cancer Res* 65:7065–7070
- Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, DiPadova F, Lin SC, Gram H, Han J (2005) Involvement of microRNA in AU-rich element-mediated mRNA instability. *Cell* 120:623–634
- Lau NC, Lim LP, Weinstein EG, Bartel DP (2001) An abundant class of tiny RNAs with probable regulatory roles in *Caenorhabditis elegans*. *Science* 294:858–862
- Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. *Cell* 115:787–798
- Lim LP, Lau NC, Garrett-Engel P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. *Nature* 433:769–773
- Liu W, Mao SY, Zhu WY (2007) Impact of tiny miRNAs on cancers. *World J Gastroenterol* 13:497–502
- Lozzio CB, Lozzio BB (1973) Cytotoxicity of a factor isolated from human spleen. *J Natl Cancer Inst* 50:535–538
- Mazière P, Enright AJ (2007) Prediction of microRNA targets. *Drug Discov Today* 12:452–458
- Nakabayashi H, Taketa K, Yamane T, Oda M, Sato J (1985) Hormonal control of alpha-fetoprotein secretion in human hepatoma cell lines proliferating in chemically defined medium. *Cancer Res* 45:6379–6383
- Puck TT, Marcus PI, Cieciura SJ (1956) Clonal growth of mammalian cells in vitro; growth characteristics of colonies from single HeLa cells with and without a feeder layer. *J Exp Med* 103:273–283
- Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P, Gardner MB (1974) Characterization of a newly derived human sarcoma cell line (HT-1080). *Cancer* 33:1027–1033
- Rehwinkel J, Natalin P, Stark A, Brennecke J, Cohen SM, Izaurralde E (2006) Genome-wide analysis of mRNAs regulated by Drosophila and Argonaute proteins in *Drosophila melanogaster*. *Mol Cell Biol* 26:2965–2975
- van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN (2006) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. *Proc Natl Acad Sci USA* 103:18255–18260
- Scherer WF, Syverton JT, Gey GO (1953) Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. *J Exp Med* 97:695–710
- Schneider U, Schwenk HU, Bornkamm G (1977) Characterization of EBV-genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. *Int J Cancer* 19:621–626
- Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V (2004) Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. *Genome Biol* 5:R13
- Sevignani C, Calin GA, Siracusa LD, Croce CM (2006) Mammalian microRNAs: a small world for fine-tuning gene expression. *Mamm Genome* 17:189–202
- Sood P, Krek A, Zavolan M, Macino G, Rajewsky N (2006) Cell-type-specific signatures of microRNAs on target mRNA expression. *Proc Natl Acad Sci USA* 103:2746–2751
- Soule HD, Vazquez J, Long A, Albert S, Brennan M (1973) A human cell line from a pleural effusion derived from a breast carcinoma. *J Natl Cancer Inst* 51:1409–1416
- Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY, Kim VN, Kim KS (2004) Human embryonic stem cells express a unique set of microRNAs. *Dev Biol* 270:488–498
- Suzuki R, Shimodaira H (2006) Pvcust: an R package for assessing the uncertainty in hierarchical clustering. *Bioinformatics* 22:1540–1542
- Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer Res* 64:3753–3756
- Tsuchiya S, Okuno Y, Tsujimoto G (2006) MicroRNA: biogenetic and functional mechanisms and involvements in cell differentiation and cancer. *J Pharmacol Sci* 101:267–270
- Zeng Y (2006) Principles of micro-RNA production and maturation. *Oncogene* 25:6156–6162

Secreted CXCL1 Is a Potential Mediator and Marker of the Tumor Invasion of Bladder Cancer

Hiroaki Kawanishi,¹ Yoshiyuki Matsui,¹ Masaaki Ito,¹ Jun Watanabe,¹ Takeshi Takahashi,¹ Koji Nishizawa,¹ Hiroyuki Nishiyama,¹ Toshiyuki Kamoto,¹ Yoshiki Mikami,² Yoshinori Tanaka,⁴ Gimán Jung,⁴ Hideo Akiyama,⁴ Hitoshi Nobumasa,⁴ Parry Guilford,^{5,6} Anthony Reeve,⁵ Yasushi Okuno,³ Gozoh Tsujimoto,³ Eijiro Nakamura,¹ and Osamu Ogawa¹

Abstract Purpose: The purpose of this study was to identify proteins that are potentially involved in the tumor invasion of bladder cancer.

Experimental Design: We searched for the candidate proteins by comparing the profiles of secreted proteins among the poorly invasive human bladder carcinoma cell line RT112 and the highly invasive cell line T24. The proteins isolated from cell culture supernatants were identified by shotgun proteomics. We found that CXCL1 is related to the tumor invasion of bladder cancer cells. We also evaluated whether the amount of the chemokine CXCL1 in the urine would be a potential marker for predicting the existence of invasive bladder tumors.

Results: Higher amount of CXCL1 was secreted from highly invasive bladder carcinoma cell lines and this chemokine modulated the invasive ability of those cells *in vitro*. It was revealed that CXCL1 regulated the expression of matrix metalloproteinase-13 *in vitro* and higher expression of CXCL1 was associated with higher pathologic stages in bladder cancer *in vivo*. We also showed that urinary CXCL1 levels were significantly higher in patients with invasive bladder cancer (pT1-4) than those with noninvasive pTa tumors ($P = 0.0028$) and normal control ($P < 0.0001$). Finally, it was shown that CXCL1 was an independent factor for predicting the bladder cancer with invasive phenotype.

Conclusions: Our results suggest that CXCL1 modulates the invasive abilities of bladder cancer cells and this chemokine may be a potential candidate of urinary biomarker for invasive bladder cancer and a possible therapeutic target for preventing tumor invasion.

Bladder cancer is the fourth most common cancer in the United States and it will be responsible for the death of an estimated 13,060 persons in the United States alone during 2006 (1, 2). Bladder cancer is generally classified into superficial (non-muscle invasive) or muscle-invasive cancer based on the natural history of these tumors. Most bladder

cancers (~80%) present as superficial tumors, which include Ta (noninvasive) or T1 (lamina propria invasive) tumor. Among these superficial tumors, ~70% recur after transurethral resection and 10% to 20% show progression to become muscle-invasive (T2-4) tumors. T1 tumors are more likely to progress to muscle-invasive disease (25-40%) than Ta tumors (3-4%; ref. 3). Muscle-invasive cancer has a much less favorable prognosis than superficial cancer (4). Due to the unfavorable prognosis of muscle-invasive cancer, there is considerable interest in developing markers that can identify superficial cancers with a high risk of progression. The identification of this type of marker will contribute to the early detection of life-threatening invasive bladder cancer and the improvement of the prognosis of this disease.

Multifocality and frequent recurrence is also another characteristic of bladder cancers (5). Multifocal tumors often present with varying degrees of stage and grade. Most studies have found only monoclonal tumors. The presence of shared genetic changes in all tumors resected from individual patients suggests that these are related lesions that have evolved from a single altered cell clone. However, there are some examples of more than one unrelated monoclonal tumor in the same bladder (oligoclonality), and this is not surprising given the association of transitional cell carcinoma risk with smoking and the pan-urothelial carcinogenic insult associated with this (6). There are two types of bladder cancer with fundamentally

Authors' Affiliations: Departments of ¹Urology and ²Pathology, Graduate School of Medicine and ³Department of Genomic Drug Discovery Science, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan; ⁴New Frontiers Research Laboratories, Toray Industries, Inc., Kanagawa, Japan; and ⁵Cancer Genetics Laboratory, University of Otago; ⁶Pacific Edge Biotechnology Ltd., Dunedin, New Zealand

Received 8/5/07; revised 12/29/07; accepted 1/17/08.

Grant support: Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Kurozumi Medical Foundation, and Takeda Science Foundation (E. Nakamura) and The New Energy and Industrial Technology Development Organization of Japan (O. Ogawa).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Requests for reprints: Eijiro Nakamura, Department of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, 606-8507 Kyoto, Japan. Phone: 81-75-751-3325; Fax: 81-75-761-3441; E-mail: hap@kuhp.kyoto-u.ac.jp.

© 2008 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-07-1922

different genetic alterations and clinical outcome. Whereas noninvasive tumors are genetically stable and characterized by frequent FGFR3 mutations and deletions of chromosome 9q, invasive bladder cancer are characterized by gross chromosomal instability and many genetic alterations. Alterations in both p53 and Rb tumor gene suppressor pathways are well documented in invasive bladder cancer. Additionally, numerous markers, such as cell adhesion molecules, tumor-associated antigens, proliferating antigens, and cell cycle regulatory proteins, have been identified, which correlate to some extent with tumor stage and prognosis (7). However, the power of many of these biomarkers in detecting superficial disease or predicting the clinical outcome of individual tumors is limited, and alternative markers are still in demand.

Secreted proteins determine, control, and coordinate many of the biological processes in organisms, such as cellular growth, differentiation, and tumorigenesis (8). After the completion of the Human Genome Project, many researchers have hypothesized that the best cancer biomarkers will probably be secreted proteins (9). Thus, great interest is currently being focused on the characterization of proteins secreted by isolated tumor cells and neoplastic tissues to identify novel biomarkers and new molecular targets for therapy.

Approximately 20% to 25% of all cellular proteins undergo secretion (10); however, the quantity of each protein secreted is usually very low. Analysis of culture supernatants after incubation of cells seems to be a reasonable way to identify such secreted proteins. However, even minor contamination with protein-rich FCS can easily mask secreted proteins of interest. Recently, we established a new method for analyzing the proteins in cell culture supernatants by using serum-free medium. Using this method, we identified clusterin as a marker for the hypoxia-inducible factor-independent function of von Hippel-Lindau protein and revealed its role in the development of familial pheochromocytoma (11, 12). In these studies, secreted proteins in the serum-free medium were precipitated with trichloroacetic acid and analyzed by two-dimensional PAGE. Then, protein spots of interest were identified by mass spectrometry (MS) analysis. Although two-dimensional PAGE provides information about the position of protein spots, it may not be so effective for detecting scarce secreted proteins (13). In the present study, we improved our method by using multidimensional shotgun proteomics, a powerful proteomics analysis tool with a high efficiency to identify hundreds of proteins in a single run (14, 15). Using this method, we compared the proteome of secreted proteins in the culture supernatant from bladder cancer cell lines with different invasive phenotypes and found that CXCL1 is overexpressed in invasive bladder cancer.

Materials and Methods

Cell lines and cell culture. Six human bladder cancer cell lines were used: DSH1 (16), KU-7 (17), RT112 (18), UMUC-3 (19), 5637 (20), and T24 (21). The cell lines were cultured in RPMI 1640 (Sigma Chemical Co.) supplemented with 10% FCS, 12.5 mmol/L HEPES, and penicillin-streptomycin at 37°C in 5% CO₂.

Cell invasion assay. BD BioCoat Matrigel Invasion Chambers (Becton Dickinson) were used. Cells were suspended to a concentration of 1×10^5 /mL in serum-free RPMI 1640. The cell suspension (500 μ L)

was added to the insert of the Matrigel-coated invasion chamber (24 well and 8- μ m pore size) and incubated with RPMI 1640 with 10% FCS in the bottom of the chamber at 37°C in 5% CO₂. Incubation time was modified according to the invasive ability of the cell lines. Noninvasive cells were removed by wiping with cotton swabs and the cells that attached to the lower surface of the membrane were fixed with 70% ethanol. Cells were then stained with hematoxylin and counted using a microscope (Eclipse E1000M, Nikon). Invading cells were quantified by counting the number of cells in the five densest spots identified on the lower surface of the filter within a single $\times 200$ field. Each experiment was done in triplicate.

Processing of cell culture supernatants. RT112 and T24 were grown to 70% to 80% confluence in RPMI 1640 with 10% FCS in 100-mm dishes. The cells were washed with PBS thrice and cultured in 10 mL serum-free RPMI 1640. In pilot experiments, we found that these cell lines proliferate for at least 2 d when grown in serum-free RPMI 1640 (data not shown). Twenty-four hours later, cell culture supernatants were collected from four dishes (40 mL) and centrifuged at 150,000 \times g and 4°C for 30 min in a Beckman Optima XL-100 ultracentrifuge (Beckman Coulter) to remove cells and cell debris completely. The supernatants were then concentrated to ~1 mL (0.6 mg/mL) by using an Amicon Ultra centrifugal filter device (15 mL, 5K NMWL; Millipore). Protein in RPMI 1640 with 10% FCS was collected in the same way as the conditioned medium and used as a control. Total protein (120 μ g) was fractionated with the ProteomeLab PF 2D Protein Fractionation System (Beckman Coulter). The separation was done using a PF2D HPRP column (Beckman Coulter) at 50°C with a flow rate of 0.75 mL/min. The column was equilibrated with solvent A [0.1% (v/v) trifluoroacetic acid in water] and eluted with solvent B [0.08% (v/v) trifluoroacetic acid in 100% (v/v) acetonitrile]. The gradient was 0% to 100% solvent B for 30 min. Eluent from column was automatically collected every 30 s into the 96-well plate with a fraction collector. Comparing the chromatogram profiles, fractions with peaks originating from FCS were excluded from further analysis. Fractions with specific peaks for cell culture supernatants were pooled into seven fractions, lyophilized, and resuspended in 100 μ L of 20 mmol/L ammonium bicarbonate buffer (pH 8.0).

Two-dimensional liquid chromatography-MS/MS and data analysis. After trypsinolysis of the fractions, two-dimensional liquid chromatography-MS/MS shotgun analysis was done by using an online nano-liquid chromatography system (Dina system, KYA Technologies) and a quadrupole time-of-flight mass spectrometer (Q-ToF Premier, Waters Micromass) as previously described (22). The identified proteins were obtained from MS/MS experiments by Mascot software (Matrix Science) using the Swiss-Prot human protein database containing 13,799 entries of human proteins (April 2006). The proteins were considered identified if they had resulting Mascot scores of >35 and at least two peptides with score >20. To determine the cellular localization of identified proteins, we used the information available from Swiss-Prot database.

cDNA microarray. Bladder cancer tissues for cDNA microarray analysis were obtained with informed consent from 55 patients who underwent surgery at our hospital. Tumor staging was assessed according to tumor-node-metastasis classifications (26 pTa, 11 pT1, 3 pT2, 13 pT3, and 2 pT4). Each bladder cancer sample was obtained by cold-cup biopsy at the time of transurethral surgery. As for the substitution of normal urothelium in the bladder, ureteral urothelium was obtained from 16 patients who had undergone nephrectomy for renal cell carcinoma. Ureteral urothelium was removed from the surgical specimen and the adjacent portion of the specimen was examined pathologically to confirm that neither urothelial dysplasia nor malignancy existed. Microarray experiments were done using a cDNA array containing ~30,000 50-mer oligonucleotides (MWG Biotech AG) fabricated by Pacific Edge Biotechnology Ltd. in New Zealand as described (23). In each hybridization, fluorescent cDNA targets were prepared from a tissue RNA sample and a reference RNA sample was derived from a pool of cell lines of different cancers. The

differences of gene expression profiles between T24 cells treated with anti-CXCL1 neutralizing antibodies or control IgG were examined by Human Genome U133 Plus 2.0 Array (Affymetrix, Inc.). cRNA preparation and hybridization to oligonucleotide arrays were according to Affymetrix protocol.

Reverse transcription-PCR. The primer sequences used for reverse transcription-PCR (RT-PCR) were as follows: CXCL1, 5'-CCA-GACCCGCTGCTG-3' (forward) and 5'-CCTCCTCCCTTCT-GGTCAGT-3' (reverse); CXCR2, 5'-ATTCTGGGCATCCTTACAG-3' (forward) and 5'-TGCACTTAGGACAGGAGTCT-3' (reverse); matrix metalloproteinase-13 (MMP-13), 5'-TCTGAATGGGCTTCCAAA-3' (forward) and 5'-GCATCTACTTATACCAATTCCT-3' (reverse); glyceraldehyde-3-phosphate dehydrogenase, 5'-GAAGGTGAAGGTCC-GAGTC-3' (forward) and 5'-GAAGTGGTATGGGATTC-3' (reverse). Glyceraldehyde-3-phosphate dehydrogenase was used as a housekeeping gene. Real-time quantitative PCR with SYBR Green was done using the GeneAmp 5700 Sequence Detection System (PE Applied Biosystems-Roche). The expression of MMP-13 was quantified relative to glyceraldehyde-3-phosphate dehydrogenase. The thermal profile consisted of 1 cycle at 95°C for 10 min followed by 40 cycles with 15 s at 95°C, 30 s at 60°C, 30 s at 72°C, and 10 s at 78°C. All measurements were done in duplicate.

Detection of CXCL1 proteins. Cells (3.5×10^5) were seeded in 60-mm dishes containing RPMI 1640 with 10% FCS. The medium was removed after 24 h, and the cells were then washed with PBS and further cultured in RPMI 1640 with 10% FCS. After 24 h, CXCL1 protein levels in cell-free culture supernatants were determined using the commercial Quantikine ELISA kit (R&D Systems) according to the manufacturer's instructions. Protein levels were corrected for the total protein in the cell lysate.

Immunohistochemical analysis. Tissues were fixed in 10% buffered formalin and embedded in paraffin. Paraffin blocks were cut at 5 μ m thickness. Sections were deparaffinized and rehydrated. For CXCL1 staining, endogenous peroxidase activity was blocked with hydrogen peroxidase. The glass slides were washed in PBS (six times, 5 min each) and mounted with 1% rabbit normal serum in PBS for 30 min. Anti-human CXCL1 polyclonal antibody (1:150; Santa Cruz Biotechnology, Inc.) was used as the primary antibody. The sections were incubated overnight at 4°C, after which Histofine Simple Stain MAX PO (Nichirei Bioscience) was applied, and the subsequent antibody/enzyme conjugate was developed with diaminobenzidine. The sections were lightly counterstained with hematoxylin. MMP-13 staining was done by using an avidin-biotinylated peroxidase complex method (Vectastain Elite ABC kit, Vector Laboratories) as described by Bostrom et al. (24). Anti-human MMP-13 monoclonal antibody was from Daiichi Fine Chemical. A brown precipitate in the cytoplasm indicated a positive immunoreactivity in both proteins. Negative controls consisted of slides where the primary antibody had been omitted. Cases were evaluated as positive staining if >10% of the cytoplasm of the tumor cells was stained. All scoring was conducted in a blind fashion by a trained pathologist (Y.M.).

Knockdown of CXCL1 by RNA interference vector. Small interfering oligonucleotides specific for CXCL1 were designed on the Takara Bio Web site⁷ and the oligonucleotide sequences used in the construction of the RNA interference (RNAi) vector were as follows: RNAi 1, 5'-GATCCGCACACTGCTCTATATATTAGTCTCTGGTTGATATAATAGGACAGTGTGCTTTTAT-3' and 5'-CGATAAAAAAGCA-CAGTGTCTCTATATCAACCAGGAGCACTAATATAATAGGACAGTGTGG-3'; RNAi 2, 5'-GATCCGCAAAATGGCCAATGAGATCAT-AGTGTCTCTGGTTGTGATCTCAITGGCCATTTGCTTTTAT-3' and 5'-CGATAAAAAAGCAAAATGGCCAATGAGATCACAACCAGGAGCAC-TATGATCTCAITGGCCATTTGCG-3'. The oligonucleotides were annealed and then ligated into *Bam*HI/*Cl*AI sites of the pSINsi-hU6 vector (Takara Bio). A retroviral supernatant was obtained by

transfection of G3T-hi cells using a Retrovirus Packaging Kit Amphi (Takara Bio). T24 cells were infected with the viral supernatant, and the cells were then selected with 750 μ g/mL G418 for 2 to 3 wk. Stable CXCL1 knockdown clones were selected and confirmed by RT-PCR and ELISA.

Establishment of stable transformants of CXCL1. The full-length human CXCL1 cDNA was generated by RT-PCR using Pfu polymerase (Stratagene) from total RNA isolated from T24. The primers used for amplification were the following: 5'-CCAGACCCGCTGCTG-3' (forward) and 5'-CCTCCTCCCTTCTGGTCAGT-3' (reverse). The PCR product was ligated into *Xho*I/*Bam*HI sites of pcDNA3.1(-) vector (Invitrogen). RT112 cells were transfected with CXCL1 cDNA using Lipofectamine 2000 (Life Technologies, Inc.). Single clones of the stable transfectants were selected with 900 μ g/mL G418. Each clone was checked for expression of CXCL1 by RT-PCR and ELISA.

Growth inhibition assay. RT112 and T24 cells (1×10^3 and 4×10^3 , respectively) were seeded into 96-well plates in quintuplicate in RPMI 1640 with 10% FCS and allowed to adhere overnight. The cultures were then washed and refed with medium. Cells were incubated for 24 to 48 h. For treatment with neutralizing antibodies, monoclonal anti-CXCL1 or control antibody (mouse IgG; R&D Systems) was added to the medium. Proliferative activity was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay using a microtiter plate reader at 540 nm.

Measurement of urinary CXCL1 levels. Clean-catch urine specimens at clinic visits were collected throughout a period of several months from patients seen in our hospital. The control group consisted of outpatients attending with diseases of the urological tracts ($n = 31$, ages 48-84 y; benign prostatic hyperplasia in 14, prostate cancer in 9, lithiasis in 4, neurogenic bladder in 2, renal cancer in 1, and adrenal tumor in 1). Bladder cancer group consists of 67 patients (ages 47-90 y) before undergoing transurethral resection of bladder tumor for later histologically confirmed urothelial cancer (32 pT_a, 23 pT₁, and 12 pT₂₋₄). There were no age differences between control group and bladder cancer group. These groups do not include the urine samples with >30 leukocytes/microscopic field. Collected samples were centrifuged for 10 min at 2,000 rpm at room temperature to remove debris, aliquoted, and stored -80°C. On the day of analysis, frozen urine samples were thawed quickly, and the urinary CXCL1 levels were measured using the Quantikine ELISA kit. Urine creatinine levels were measured spectrophotometrically using the alkaline picrate method.

Statistical analysis. The raw microarray data were analyzed using the nonparametric Mann-Whitney *U* test to compare the gene expression level between noninvasive pT_a tumors and invasive pT₁₋₄ tumors. The results of urinary CXCL1 levels were analyzed using the Mann-Whitney *U* test for two-group comparisons. The optimal sensitivity and specificity of the urinary CXCL1 levels for diagnosis of bladder cancer and for staging were determined by receiver operating characteristic (ROC) curve analysis using R statistical package. Univariable and multivariable logistic regression models were used to calculate odds ratios and 95% confidence intervals. Statistical analysis of the data was done using the StatView-J 5.0 program (Abacus Concepts, Inc.). A value of $P < 0.05$ was considered statistically significant.

Results

Evaluation of in vitro invasiveness of bladder cancer cell lines and their proteome in cell culture supernatant. We chose six different bladder cancer cell lines. Of them, three cell lines, DSH1, KU-7, and RT112 cells, are commonly used as models of superficial bladder cancer and UMUC-3, 5637, and T24 cells are generally used as models of invasive bladder cancer. Then, we examined their invasion ability *in vitro* by using a modified Boyden chamber assay. As shown in Fig. 1A, the number of cells infiltrated was higher in the latter group of cells; this result

⁷ <http://www.takara-bio.co.jp/>




Fig. 1. A. invasion of bladder cancer cell lines in a modified Boyden chamber. Cells (5×10^4) were seeded into the upper compartment of the chamber in serum-free RPMI 1640 and incubated for 24 h at 37°C . RPMI 1640 with 10% FCS filled the lower compartment. Columns, mean of the number of cells in the five densest spots identified on the lower surface of the filter within a single $\times 200$ field in each of three experiments; bars, SD. B. reverse-phase chromatograms of cell culture supernatants. Eluted proteins were detected by UV absorbance at 214 nm. In T24 and RT112 supernatant, peaks originating from FCS are indicated by arrows. The fractions from 11 to 23 min were collected for two-dimensional liquid chromatography-MS/MS analysis. C. schematic flow diagram depicting the steps for identifying proteins associated with invasion by human bladder cancer.

indicated that UMUC-3, 5637, and T24 are highly invasive, whereas DSH1, KU-7, and RT112 are poorly invasive tumor cells. DSH1 and RT112 showed almost no invasion ability and T24 cells exhibited the strongest invasive ability.

Because secreted proteins are thought to be suitable targets for the development of diagnostic markers and/or for identification of new drug targets (8, 9), we attempted to identify secreted proteins that were potentially involved or associated with the invasion of bladder cancer through the proteomic comparison of culture supernatants from highly invasive T24 and less invasive RT112 cells. As protein-rich FCS could easily mask proteins of interest in this analysis, we used serum-free medium as described previously (11, 12) and excluded contamination as far as possible by removing chromatogram fractions with peaks originating from FCS. As shown in Fig. 1B, fractions eluted from 11 to 23 min, which seemed to be produced from cultured cells, were pooled and analyzed by shotgun proteomics. A total of 477 proteins were identified in the culture supernatants of RT112 and T24 cells (218 and 295 proteins, respectively). Swiss-Prot database annotated the cellular localization of 330 proteins and 43 of them were predicted to be secreted proteins (Fig. 1C). Of these secreted proteins, 22 of them were detected only in highly invasive T24 cells (Supplementary Table S1).

Up-regulation of CXCL1 in invasive bladder tumors in vitro and in vivo. To further investigate the significance of these proteins in the invasion of bladder cancer, we compared the proteome data with mRNA expression profiles that consisted of 26 noninvasive pTa tumors and 29 invasive pT1-4 tumors *in vivo* (23). Among those 22 proteins specific for highly invasive T24 cells, there were corresponding probe sets for 14 of them on the custom-made chips. Of them, the expression of

CXCL1 was significantly higher in invasive tumors than in noninvasive tumors *in vivo* (Fig. 2A). Additionally, the expression of this gene was more abundant in tumor tissues compared with that in normal uroepithelial cells. To confirm these results, the expression of this gene was examined in bladder cancer cell lines by using RT-PCR. It was revealed that all of the three highly invasive cell lines (UMUC-3, 5637, and T24) expressed CXCL1, whereas neither of them was detected in the less invasive DSH1, KU-7, and RT112 cell lines (Fig. 2B).

Because CXC chemokines are known to contribute to several tumor-related processes, such as tumor growth, angiogenesis/angiostasis, local invasion, and metastasis (25), we next examined the significance of CXCL1 in invasion of bladder cancer cell lines *in vitro*. First, we confirmed that all of the invasive cell lines secreted CXCL1 into the supernatants, whereas none of the less invasive cell lines secreted the detectable levels of this chemokine (Fig. 2C). These results indicate that higher secretion of CXCL1 is associated with the higher invasion ability of bladder cancer cells *in vitro*. It was also confirmed that CXCR2, the gene for the receptor of CXCL1, was expressed in all of bladder tumor cell lines irrespective of their invasion ability (Fig. 2B). Because CXCL1 was highly expressed at the mRNA level in invasive bladder tumors *in vivo*, we next examined if this chemokine is also up-regulated at the protein level. Representative results of immunohistochemical staining are shown in Fig. 2D. It was revealed that positive staining was observed in none of the normal uroepithelium samples and in 40% of pTa tumors. On the other hand, as many as 75% of pT1-4 tumors stained positive. These observations led us to hypothesize that the expression of CXCL1 was related to tumor invasion of bladder cancer *in vivo*.

Secreted CXCL1 is sufficient for increased invasion by bladder cancer cells. Next, we clarified whether CXCL1 regulated the invasive ability of bladder cancer cells *in vitro*. We first examined the effect of knockdown of CXCL1 in highly invasive T24 cells by using RNAi vectors. We have established two different polyclones in which the expression of CXCL1 is reduced by 30% compared with mock-transfected control cells (Fig. 3A). It was revealed that this inhibition of CXCL1 expression decreased the number of infiltrated cells in the invasion assay to 30% (Fig. 3B). Because the treatment of T24 cells with anti-CXCL1 neutralizing antibodies resulted in comparable reduction in the number of infiltrating cells, these results suggest that secreted CXCL1 regulates the invasive ability of bladder cancer cells via an autocrine loop (Fig. 3C). As CXCL1 has previously been shown to stimulate cell proliferation as an autocrine growth factor in several cancer cell lines (26, 27), we examined the effect of this chemokine on cell proliferation. As shown in Fig. 3D, the knockdown of CXCL1 or its neutralization with specific antibodies showed no direct effect on proliferation of T24 cancer cell lines. These results indicated that secreted CXCL1 in the supernatant promotes the invasion of T24 cells but has little effect on the proliferation of these cells.

To examine if the expression of CXCL1 is sufficient to promote the enhanced invasion of bladder cancer cell lines, less invasive RT112 cells were stably transfected with a plasmid that encoded CXCL1 and two independent monoclonal antibodies were established. Both monoclonal antibodies successfully secreted large amounts of CXCL1 and showed higher invasive ability compared with mock-transfected control cells (Fig. 3E). These results indicated that the expression of CXCL1 is sufficient to promote the enhanced invasion of bladder cancer cells *in vitro*. As observed for T24 cells, this effect was suppressed by

treatment with anti-CXCL1 neutralizing antibodies and the forced expression of this chemokine had no effect on the proliferation of RT112 cells (data not shown).

CXCL1 regulated the expression of MMP-13 in bladder cancer cells *in vitro* and the expression of CXCL1 was associated with that of MMP-13 *in vivo*. To clarify the mechanisms by which CXCL1 regulates the invasive ability of bladder cancer, we compared the mRNA expression profiles of highly invasive T24 cells treated with or without an anti-CXCL1 neutralizing antibody using the Affymetrix U133 Plus 2.0 Array. Among the 38,500 transcripts analyzed, we identified 62 RNAs whose abundance was decreased (<0.6-fold) by treatment with an anti-CXCL1 neutralizing antibody (Supplementary Table S2). It was revealed that a member of the MMP family, MMP-13, was down-regulated by the inhibition of CXCL1. To confirm this result, we examined the expression of MMP-13 in T24 and RT112 cells in which CXCL1 was engineered to be repressed or overexpressed, respectively. It was revealed that the expression of MMP-13 was regulated by the expression of CXCL1 in both cell lines (Fig. 4A). Because it has been reported that the expression of MMP-13 is associated with the invasion of bladder cancer *in vivo* (24), we next examined if the up-regulation of CXCL1 is associated with the higher expression of MMP-13 in bladder cancer cells *in vivo*. Positive staining of MMP-13 was observed in none of 11 tumors (6 with pTa, 4 with pT1, and 1 with pT3) with negative staining of CXCL1, whereas it was observed in 9 (1 with pT1, 7 with pT3, and 1 with pT4) of 19 (4 with pTa, 5 with pT1, 1 with pT2, 7 with pT3, and 2 with pT4) tumors with positive staining of that chemokine (Fig. 4B). It was revealed that statistically significant correlation was observed between the expressions of both proteins ($P = 0.0064$, χ^2 test). These results suggest the possibility that MMP-13 is also regulated by CXCL1 *in vivo*.

Fig. 2. A, cDNA microarray data for CXCL1. The normalized expression units of this gene were transformed into the log₂ values. Bars of the box extend from the 25th to 75th percentile of the data and the line in the middle represents the median. The upper and lower bars represent the distance from the 10th to 90th percentile from the median. The Mann-Whitney *U* test was used to compare expression levels between the two groups. B, expression of CXCL1 and CXCR2 mRNA by bladder cancer cell lines with different levels of invasiveness. The PCR conditions are as follows: denaturation (95°C, 5 min), 32 cycles of denaturation (94°C, 1 min), annealing (58°C, 1 min), and extension (72°C, 1.5 min). GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Values were corrected for the total protein in the cell lysate. C, expression of CXCL1 protein by bladder cancer cell lines. Protein levels in cell culture supernatants were analyzed by ELISA. Each cell line was plated in triplicate; experiments were repeated at least twice. Bars, SD. D, immunohistochemical staining for CXCL1 in surgical tissue specimens. A brown precipitate in the cytoplasm denotes positive signal. Representative samples of negative (a, normal uroepithelium; b, pTaG1) and positive (c, pT2G3; d, pT3G3) staining are shown. Bars, 100 μ m.

